Seattle Genetics, a fast growing company in the cancer research community, was honored by a visit by the vice president Joe Biden. Joe Biden opted to visit the company due to their outstanding innovations in developing antibody-drug conjugates for the treatment of cancer.
Seattle Genetics is currently marketing its first brand of drugs known as Adcetrics. The brand was approved in August 2011. The company has been testing the efficacy of Adcetrics in the management of lymphoma. In a conference held at world trade center, Seattle Genetics’ CEO and president, Clay Siegall, confirmed that the drug had been used in the treatment of more than 15,000 lymphoma patients worldwide.
To meet the excellent treatment standards of the drug, Seattle Genetics was conducting the third advanced clinical trial on the drug. The advanced testing uses Adcetrics as the first treatment for new cases of lymphoma. Based on the trials, the drug is reported to have shown positive results.
In a meeting held with the company’s investors, Seattle Genetics’ management confirmed that it was confident that the sales of Adcetrics would increase. In 2015, the company made estimated sales of $226 million in United States and Canada. In this year, the company expects to record sales of between $255 million and $275 million. To grow its market outside Canada and US, the firm contracted Takeda Pharmaceuticals, a global drugs’ distributor.
Seattle Genetics is developing 12 other drugs to add up to Adcetrics. It is planning to release a different drug branded 33A for advanced trials. 33A was prepared to treat acute myeloid leukemia. The company has developed two other drugs that will be used to treat breast cancer and bladder cancer.
In a plan to expand its international market, Dr. Clay Siegall announced that the company wishes to recruit 100 employees and 20 others in US and in Switzerland respectively.
Dr. Siegall has a long experience working in the pharmaceutical industry. Besides working as the CEO of Seattle Genetics company, he is a member of the board of directors of Alder Biopharmaceuticals. He has also formed affiliations with various pharmaceutical companies to help Seattle Genetics to come up with better cancer therapies.
Keep on reading…